# Epanova® for Lowering Very High Triglycerides

Study · id `cardio:ct-nct01242527` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01242527](<https://clinicaltrials.gov/study/NCT01242527>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01242527

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 399 participants.

## Technical summary

Registry record NCT01242527. Randomized; quadruple masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2013-09-06.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 399 participants (enrolled count; ClinicalTrials.gov record NCT01242527, source copy `cardio:ctgov-nct01242527-2016-08-04`, retrieved 2026-10-31)
- Start date: 2011-01 (registry gives no type) (ClinicalTrials.gov record NCT01242527, source copy `cardio:ctgov-nct01242527-2016-08-04`, retrieved 2026-10-31)
- Primary completion: 2012-03 (actual) (ClinicalTrials.gov record NCT01242527, source copy `cardio:ctgov-nct01242527-2016-08-04`, retrieved 2026-10-31)
- Completion: 2012-04 (actual) (ClinicalTrials.gov record NCT01242527, source copy `cardio:ctgov-nct01242527-2016-08-04`, retrieved 2026-10-31)
- Results first posted: 2013-09-06 (ClinicalTrials.gov record NCT01242527, source copy `cardio:ctgov-nct01242527-2016-08-04`, retrieved 2026-10-31)
- Countries: United States; Denmark; Hungary; India; Netherlands; Russia; Ukraine (ClinicalTrials.gov record NCT01242527, source copy `cardio:ctgov-nct01242527-2016-08-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01242527-2016-08-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: Epanova® for Lowering Very High Triglycerides
- Acronym: EVOLVE
- Condition: Severe Hypertriglyceridemia
- Intervention (Drug): placebo
- Intervention (Drug): omefas
- Intervention (Drug): omefas
- Intervention (Drug): omefas
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial (`cardio:pubmed-24528690`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 62bd41bdc88171e2f31c73131191523f60df03c6b0f77ccda91080ae9cc7c975
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
